The decision is anticipated by 25 November 2026.

Sanofi’s venglustat accepted for priority review in the US to treat type 3 Gaucher diseaseParis, May 28, 2026. The US Food and Drug ...

Sanofi is developing custom tools and reimagining AI workflows, rather than rely on agentic products sold by SaaS vendors.

The FDA has started a priority review of Sanofi's Gaucher disease therapy venglustat, a potentially first-in-class therapy, ...

On May 18, 2026, Sanofi reported phase 2 data from the global ElevAATe trial showing its investigational recombinant therapy efdoralprin alfa outperformed plasma-derived standard-of-care augmentation ...

Sanofi reported that its investigational drug efdoralprin alfa showed clear superiority to standard-of-care therapy in a phase 2 trial for AATD-related emphysema. The phase 2 ElevAATe study found ...

By Bhanvi Satija and Mariam Sunny LONDON, April 23 (Reuters) - French drugmaker Sanofi on Thursday reported first-quarter profit and revenue above market expectations, boosted by resilient demand for ...

Sanofi stock: recent move and performance context Sanofi (ENXTPA:SAN) stock has been under pressure, with the share price ...

(Reuters) -Sanofi's most advanced multiple sclerosis drug candidate has missed the main goal of two late-stage trials to treat relapsing forms of the disease, but in a positive surprise succeeded in a ...

Sanofi ( (SNY)) just unveiled an announcement. At its mixed Annual General Meeting on April 29, 2026 in Paris, Sanofi’s shareholders approved all resolutions, including the appointment of former Merck ...

A visitor looks at the introduction of medicines for vaccines and chronic diseases at the Sanofi booth at the 5th CIIE in ...

A phase 2 trial of Sanofi's experimental therapy for alpha-1 antitrypsin deficiency (AATD) has raised the hope of an ...